Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 18/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 11/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.40 |
| ▸ | UTRN | P46939 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24819865 | 1.00 | VSIR (0.43) | VSIRPDCD1CD274UTRNKDM4E | |
| SCHEMBL30152638 | 0.89 | VSIR (0.44) | VSIRPDCD1CD274 | |
| SCHEMBL30153122 | 0.89 | VSIR (0.37) | VSIRPDCD1CD274UTRN | |
| SCHEMBL24818960 | 0.89 | VSIR (0.44) | VSIRPDCD1CD274 | |
| SCHEMBL24820540 | 0.89 | VSIR (0.37) | VSIRPDCD1CD274UTRN | |
| SCHEMBL24818740 | 0.89 | VSIR (0.44) | VSIRPDCD1CD274MAPTHPGD | |
| SCHEMBL24819921 | 0.87 | VSIR (0.43) | VSIRPDCD1CD274SMN1; SMN2 | |
| SCHEMBL30152902 | 0.86 | VSIR (0.41) | VSIRPDCD1CD274UTRNKDM4E | |
| SCHEMBL24819911 | 0.86 | VSIR (0.41) | VSIRPDCD1CD274UTRNKDM4E | |
| SCHEMBL24819883 | 0.86 | VSIR (0.42) | VSIRPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | VSIR 1674/4885PDCD1 1429/4885CD274 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.